➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
Harvard Business School
McKinsey
AstraZeneca
McKesson
Mallinckrodt

Last Updated: April 11, 2021

DrugPatentWatch Database Preview

Litigation Details for Novartis AG v. Ezra Ventures LLC (D. Del. 2015)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Small Molecule Drugs cited in Novartis AG v. Ezra Ventures LLC
The small molecule drug covered by the patents cited in this case is   Start Trial .

Details for Novartis AG v. Ezra Ventures LLC (D. Del. 2015)

Date Filed Document No. Description Snippet Link To Document
0000-00-00 187 expiration date of unasserted U.S. Patent No. 6,004,565 ("the ' 565 patent"). The Court heard oral… of the patent term extension ("PTE") of the '229 patent. The ' 229 patent discloses…565 patent, extension of the ' 229 patent beyond the expiration date of the '565 patent violates…double patenting analysis requires construction of claims in earlier patent and later patent, followed…alleging infringement of U.S. Patent No. 5,604,229 ("the ' 229 patent") based on Ezra' External link to document
2016-01-25 70 expiration date of United States Patent No. 6,004,565 (“the ’565 patent”). … of the Patent Term Extension (“PTE”) of United States Patent No. 5,604,229 (“the ’229 patent”) past … 2015 9 June 2017 1:15-cv-00150 830 Patent None District Court, D. Delaware External link to document
2016-01-25 71 expiration date of United States Patent No. 6,004,565 (“the ’565 patent”). 2. As outlined… C. The Patent Term Extension of the ’229 Patent Is Invalid For Double Patenting ........… of the Patent Term Extension (“PTE”) of United States Patent No. 5,604,229 (“the ’229 patent”) past …after the ’565 method patent. (Ex. B) Notably, the ’229 patent and the ’565 patent are not related through…of the ’565 method patent. C. The Patent Term Extension of the ’229 Patent Is Invalid For Double External link to document
2016-02-29 96 covers Gilenya®, U.S. Patent No. 6,004,565. Section 156, however, plainly allows patent- holders to choose…chose the ’229 patent. The Patent Office and FDA approved the extension of the ’229 patent term. Ezra makes…argument that double patenting prohibits a patent-holder from choosing a patent that would otherwise …other, related patents. II. The ’229 Patent and File History The ’229 patent arose from an…The ’565 Patent and File History The patent application giving rise to the ’565 patent was filed External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
Mallinckrodt
Colorcon
Baxter
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.